Ep. 124: Real Income vs. Manufactured Yield — What Actually Funds the Payout

Welcome to today's deep dive.
So when you look at your investment portfolio and, you know, you see a stock or a fun
flashing a 6% a 10% or maybe even a 20% yield, which is crazy to see.
Right. It is. But do you actually know where that cash is coming from?
Most people don't. Exactly. Because, I mean, we all love seeing that deposit hit the account.
But there is this massive hidden gulf between a business actually earning that money.
And, well, a financial structure, just taking your own capital and handing it back to you in
a different envelope. Yeah, it really is. It's the ultimate magic trick of the financial world.
We look at the shiny object, like the payout itself. And we completely ignore the mechanics
happening behind the curtain. Which is dangerous. Incredibly dangerous. So to survive in today's
market, you really have to separate three concepts that, well, most investors completely blur
together. First, there's the distribution rate. That's just the cash hitting your account,
the shiny headline, like the billboard number essentially. Exactly. The billboard. Then you have
the SEC yield, which is a measure of real income. So this tells you what the underlying business or fun
actually earned from its operations or its interests. Okay. So that's the real money made.
Right. And then finally, there's total return. And that is the price change of the asset plus
those distributions. Because, you know, if you aren't tracking total return, you have absolutely no
idea if you are actually getting wealthier. Let's put that framework to the test and let's start
at the absolute extreme end of the yield spectrum. Let's do it. What if I told you that you could get
a 20% distribution right now? People would jump at that. They would. So let's break down the NEO's
XQQI fund. Because the numbers here are just wild. It has a declared distribution that annualizes
to a run rate of 20.08%. Wow. And the trailing 12 month yield sits at 12.01%. But here is the
structural catch. The 30 day SEC yield. So the actual net investment income is negative.
0.34%. Negative. Negative. I mean, how is a fun paying out 20% when its actual income is below zero?
Well, this comes down to pure financial engineering. It's really fascinating. XQQI owns the Nasdaq
100 index, but they don't stop there. They bolt on leverage using something called a synthetic
long. Okay. So synthetic long. Yeah. And to do this, they buy index call options and they sell index
put options at the exact same strike price. Okay. Walk me through the mechanics of that though. Like,
why go through the trouble of buying calls and selling puts instead of just, you know, buying more
the index? Mostly because it's incredibly capital efficient. The premium they collect from selling
the puts essentially pays for the calls they buy. Oh, I see. Right. So it mimics the experience of
owning the index. They participate in the upside and the downside. But it doesn't tie up their cash.
And this structural maneuver gives the fund roughly 150% exposure to the Nasdaq 100, which is a lot
of exposure. It is. And because they have that 150% exposure, they can sell 50% more covered calls
against that position than a standard unleveraged fund could. And selling those covered calls is what
generates that massive stream of option premium. But if they're generating all that premium,
why is the SEC yield negative? I mean, where's the disconnect? So the disconnect is because option
premium is generally treated as capital gains or more importantly, return of capital. It's not
traditional income, like, say, a company paying a dividend from its corporate profits. What?
Return of capital literally means it is your own money coming back to you. The fund itself isn't
generating traditional income. The cash lands in your account. And sure, it's real cash,
but you are slowly eating your own principle to get it. Hold on. So if they're just returning capital
to manufacture this massive payout that feels a bit like, well, it's like a bakery claiming they
have record breaking profits, but it turns out they're just selling off their own ovens to pay the
chair holders. That is a phenomenal way to visualize it. I mean, it's not a scam. It's just a highly
specific tool since its inception in February, 2026. XQQI actually has a total return of 12.53%.
Oh, really? Yeah. So in a rising market, the strategy has worked. Your wealth did grow,
but you really have to understand the asymmetric risk they're taking to pull this off.
I think his leverage cuts both ways, right? Infatically, yes. The leverage is symmetric on the way down.
So if the Nasdaq falls 20%, XQQI's 150% exposure means it feels a 30% drop.
Out trade. Right, but remember those covered calls they sold to generate the yield? Yeah.
Well, selling a covered call means you're capping your upside. You agree to sell at a set price.
If the market rockets past that, you don't get to participate in those gains. So you get all the pain
on the way down the actually amplified pain, but you don't get the full recovery on the way out.
Exactly. Digging out of a hole becomes incredibly difficult. We saw a flash of this in April's
brief sell-off actually. XQQI dropped roughly 12% while the main index held up much better.
Plus, you know, you're paying a 1% expense ratio for this engineering compared to just 0.18%
for a basic QQQ index fund. So it's a very specialized tool with very real structural caps.
Yes, definitely. But, you know, if engineered yields are essentially a magic trick returning
our own money, what happens when we look at companies that actually loan out real cash?
Right. The real lenders. Yeah, you'd think business development companies, BDCs, and mortgage
reeds would be the ultimate safe haven for real yield. You would think that. But the market usually
prices in a reality that retail investors just miss. A 12% or 15% yield is often the market
telegraphing a dividend cut. Basically warning you. Exactly. Let's look at Saratoga investment core,
ticker, SAR. They pay a 25-cent monthly distribution. But for six straight quarters,
they have not generated enough net investment income to cover it. Six quarters. Just writing checks
the businesses and caching. Yep. And their net asset value, which is the actual underlying worth
of their loan portfolio, is declining while they try to maintain this payout. That sounds completely
unsustainable. It is an unsustainable trajectory. They are dipping into spillover income from past
years to cover the shortfall. But you know, that will rendry. Right. Or consider Aries commercial real
estate ticker HRE. This is a mortgage rate. And they're just drowning in non accruals on office buildings.
Well, commercial office real estate in 2026 is a brutal place to be a lender right now.
It really is. And a non accrual simply means the borrower has stopped paying interest. It does
this. A series payout ratio hit a staggering 125%. Wow. So they are paying out 25% more cash
than their portfolio is generating. Exactly. Or look at the CLO fund, Oxford Lane Capital,
OXLC. Their underlying investment portfolio is shrank by nearly 40% in just one year.
40% in a year. Yeah. And the net asset value dropped by almost half. When the pool of assets generating
your income shrinks by 40%. The payout. Well, it just has to follow. It has to. But let me
challenge that a bit because not all BDCs are drowning in bad loans. Right. Sure. I was looking at
golebb capital ticker GBDC before we started. Their non accruals are only sitting at 1.9%. That doesn't
sound disastrous at all. Yet they are still flagged as a major risk in high yield debt. Why is that?
Uh, so this is where we have to talk about PEC or payment in kind. Okay. PEC at 1.9% the true
defaults are low. But the hidden danger is the PIK income. Payment in kind means the
borrower isn't actually paying golebb capital and cash. Wait. How are they paying them then?
Well, the borrower is just adding the interest they owe to their total loan balance. They are
essentially borrowing more money just to pay the interest. Wow. So basically if I owe you 100 bucks
in interest instead of handing you a check, I just say, Hey, add it to my tab. My loan is now larger.
Exactly. And you get to record $100 in income on your balance sheet. But your actual bank account
hasn't changed at all. You've got it. It is phantom income. It makes the earnings look perfectly
fine on an accounting spreadsheet. But I mean, you cannot pay a cash dividend to your shareholders
using a borrower's IOU. Right. The shareholders expect real cash. Exactly. And when you strip out
that phantom PIK income from golebb capital earnings, the actual cash they're bringing in does not
cover the dividend they're paying out. That is wild. Okay. So obscure credit funds and highly
leveraged ETFs carry strange risks. We get that. Right. But what about a massive household name?
People see a famous logo yielding 6% and they just assume it's bullet price. Oh, all the time.
And right now we're seeing some of the most famous brands in the world hitting five year high yields.
Like let's look at Pfizer ticker PFE yielding a massive 6.4%. So Pfizer is actually the perfect case
study of a blue chip value trap. The stock is down over 40% in the last five years, which is a huge
drop for a company that's massive. They saw this massive revenue boom during COVID hitting around
$100 billion in 2022. But that revenue has totally flatlined their guiding for 60.5 to 62.5 billion
for 2026. So basically zero growth from 2025 zero. But wait, let me push back on this a little because
there is a very vocal bull case for Pfizer right now. You heard it. Yeah. Right. They have a Ford PE
ratio of just 8.5, which is dirt cheap for big pharma. It is low. And furthermore, two of their
directors just bought shares on the open market. I think those are the first insider buys we've seen
in over a year and a half. Okay. True. So is it possible the broader market is just way too pessimistic
about their pipeline? I mean, they have an obesity drug and phase three trials. They have new oncology
treatments. It's well, it is always possible. Pipeline drug hits a home run. Yeah. Sure. But as an
income investor, you cannot pay your mortgage with a phase three clinical trial. That's a very
fair point. Right. You have to look at the cold hard cash flow today. And in the first half of
2026, Pfizer paid out 4.9 billion dollars in dividends. That puts them on a 9.8 billion dollar annual
pace. Yeah. But their total free cash flow for all of 2025 was only 9 billion dollars. So they
are literally eating their own cash reserves to mail out those dividend checks. Yes. They are
dipping into reserves or they're relying on debt just to cover the shortfall. And the headwinds are
massive by 2028. Pfizer faces a brutal patent cliff. Oh, the patent expiration. Right. They are going
to lose patent protection on a blood thinner that generated 8 billion dollars and a breast cancer
drug that generated 4 billion dollars. Wow. That is 12 billion dollars in revenue completely exposed
to generic competition in the very near future. And pharmaceutical cash flows are already so unpredictable
as it is. Which is exactly why management language is the ultimate tell. Historically, Pfizer's stated
goal to shareholders was to grow the dividend. Right. That's the standard line. But recently,
they have openly shifted their language to simply maintaining the dividend. Oh, wow. That's a big shift.
It's huge. When a company with stagnant revenues, looming patent cliffs and a cash flow deficit
tells you they're just trying to hold the line. Well, that 6.4% yield is a warning siren. It's not a
bargain. That is a harsh reality check. But it perfectly sets up the free cash flow payout ratio
test. Because, you know, not every blue chip with a historically high yield is a trap. No, absolutely
not. Let's apply this test to some consumer brands, like Nike, PepsiCo and McDonald's. Yeah,
this test really separates the wheat from the chaff. Take Nike, ticker NKE, it's trading at a 3.9%
yield, which is in the 99th percentile for them historically. Really high for Nike. Very high.
The stock is down 75% over five years. But when you look at their free cash flow payout ratio,
it hit 110% in 2026. Oh, just like Pfizer. So they're paying out more cash than the business actually
generates. Exactly. But then look at PepsiCo, ticker PEP, they are yielding 4.31%, which is also
incredibly high for them. Right. The underlying math, however, is totally different. Pepsi generates
$9.2 billion in free cash flow over the trailing 12 months, which easily covers the 7.8 billion
they pay out in dividends. So the cash is actually there. The cash is there. And McDonald's ticker
MCD is sitting at a 2.72% yield near its 5-year high. But their free cash flow payout ratio is a very
comfortable 71%. That's a huge difference. It is. The lesson is clear. A high yield on a famous brand
is only a true bargain if the free cash flow actually exists to pay it. Pepsi and McDonald's pass the
test. Nike and Pfizer are heavily constrained. Okay. So engineered yields are returning our own capital.
BDCs are struggling with phantom income. And some of our biggest blue chips are cannibalizing their
own cash flow. It sounds pretty bleak when you put it like that. It does. So is there any sector
left in this market that actually throws off boring, fully funded real cash flow? Like where do you
go for a real yield? You go to energy infrastructure, specifically midstream MLPs. Okay, break that down
for us. Why is midstream energy fundamentally different from just buying an oil major like Exxon or
Chevron? Well, it is an entirely different business model. Midstream companies operate the
pipelines, the storage terminals, and the processing plants that physically move the oil and natural gas
across the country. Okay. But they generally do not own the commodities themselves. They operate on
fee-based contracts. Ah, so instead of trying to predict the price of oil or spinning up some synthetic
leverage, these companies are basically just running massive industrial toll booths. Exactly,
toll booths. They charge a toll for the volume moving through the pipe. If crude oil drops from
$80 a barrel down to $60 a barrel, the pipeline operator still gets paid their fee for every single
barrel that moves from point A to point B. So it's a volume business, not a price business.
You got it. And this structure largely shields them from those wild boom and bust swings and commodity
prices. It gives them incredibly clear, multi-year cash flow visibility. And looking at our sources,
the numbers right now back that up. Oh, completely. In 2026, midstream MLPs are generating some of the
highest free cash flow yields in the entire equity market. The Allarian MLP index, the AMZ,
and the infrastructure index, the AMZI, are currently yielding 6.4% and 6.7%. Which is very strong.
It is. But unlike the BDCs or Pfizer, these payouts aren't just surviving. They're actively growing.
Because real free cash flow allows for real dividend growth. Enterprise products partners,
ticker EPD, just hikes their quarterly distribution to 56 cents. Nice. Yeah. And MPLX expects 12.5%
annual growth in their payouts through 2026 and 2027. Sonoco ticker SUN targets 5% multi-year growth.
Wow. Energy transfer, ticker ET, is steadily growing their payouts as well. Over 80% of the AMZ
index by waiting has increased distributions in the last year alone. It is wild to compare that
to the struggles we saw elsewhere. It's night and day. A 6.4% yield that is fully funded by cash flow
growing every year. And on top of that, the total return for these indexes is up over 18% year-to-date.
You get the real income and you get the underlying capital appreciation. Yeah, because the underlying
businesses are thriving and reinvesting rather than cannibalizing themselves to pay the dividend.
I do have to play devil's advocate here though. Go for it. MLPs are fantastic businesses,
but they are still equities. They are still stocks. Sure. So if the broader stock market takes a 20%
dive, pipelines are still going to feel the collateral damage. If an investor is looking for true structural
safety, where is the ultimate hiding place? This brings us to the final piece of the puzzle and
arguably the most misunderstood in today's environment core bonds. But wait, looking at the landscape
of 2026, the Morningstar U.S. Core Bond Index is actually slightly down for the year. Yeah,
it has been tough. We're dealing with sticky inflation and these higher for longer interest rates.
So why are we talking about funds like the Vanguard total bond market, BND, or dodging
cox income, DODX, as a safety net if they're basically treading water or losing money?
Because you have to honestly ask yourself what role the bond is playing in your portfolio.
You don't buy a broad market core bond fund for a massive sexy headline yield. You buy them for
ballast. Ballast? Like the heavyweight in the hole, keeping a ship upright when the equities market
capsizes. Exactly. Look at the hard evidence from this year alone. When the stock market panicked
over shifts in artificial intelligence sentiment, or when geopolitical fears spiked around the
Middle East, equities dumped. Right, we saw some sharp drops. But bonds absorb the shock. They either
gained value or they suffered far milder losses, which significantly muted the overall volatility
of a portfolio. So core bonds represent the truest form of real yield. It's not glamorous,
it's not a 20% headline rate generated by options. But it's the unglamorous anchor that allows you to
confidently take risks in other areas of your portfolio, like those MLPs or those blue chip stocks.
Exactly. If you're chasing yield in equities, even high quality ones, you are inherently taking
on risk. Bonds are the structural counterbalance to that risk. They ensure that when the unexpected
happens, your entire portfolio doesn't capsize. Well, let's bring this all together. We went on
quite a journey today across the entire yield spectrum. We really did. We learned that when you see
a 20% distribution rate, like with the XQQI fund, there's a very good chance that a huge chunk of that
is just your own capital being handed back to you. The negative SEC yield tells the true story of what
the fund actually earns. Right. And we also saw that high yields from lenders struggling with
phantom P.I. Hay income or blue chips like Pfizer eating their own cash reserves. Well, that can be a
mirage. If the business is shrinking or if they're paying out more free cash flow than they generate,
that dividend is incredibly fragile. But we found the real cashbacked income hiding out in midstream
energy MLPs, you know, running those industrial toll booths, ignoring commodity prices and generating
massive free cash flow. And we remembered that core bonds are there to be the boring, reliable
ballast when the waters get choppy. The biggest takeaway for you listening right now is this.
The next time you see a juicy yield, do not just look at the headline distribution rate.
Please don't. The very first question you much ask yourself is, what actually funds the payout?
Is it cash from operations? Is it borrowed money? Or is it just financial engineering?
Which leaves us with this final thought to chew on? In a world that is completely obsessed with
headline distribution rates, what happens when an entire generation of income investors eventually
realizes their yield was just their own capital being handed back to them in a different envelope.
When the music finally stops, who is left holding the real cash? Think about that next time you look
at your portfolio. Thanks for joining us on this deep dive and we'll catch you on the next one.